Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences

Toxicological Reviews

Volumn 25, Issue 2, 2006, Pages 79-85

  Mégarbane, Bruno ^a,b   Hreiche, Raymond ^a   Pirnay, Stéphane ^a,c   Marie, Nicolas ^a   Baud, Frédéric J ^a,b  

^a HÔPITAL FERNAND WIDAL   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c Centre Universitaire des Saints Pères   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; BENZODIAZEPINE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CYTOCHROME P450 3A4; DIAZEPAM; DRUG METABOLITE; FLUNITRAZEPAM; MACROLIDE; METHADONE; MIDAZOLAM; MORPHINE; NALOXONE; NORBUPRENORPHINE; OPIATE; PROTEINASE INHIBITOR; PSYCHOTROPIC AGENT; SEDATIVE AGENT; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ASPHYXIA; DIZZINESS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG MISUSE; DRUG SAFETY; HEADACHE; HEROIN DEPENDENCE; HUMAN; MAINTENANCE THERAPY; NAUSEA; NONHUMAN; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SWEATING; VOMITING; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; ANTI-ANXIETY AGENTS; ASPHYXIA; BENZODIAZEPINES; BUPRENORPHINE; DRUG INTERACTIONS; HEROIN DEPENDENCE; HUMANS; RESPIRATORY INSUFFICIENCY;

EID: 33748590504     PISSN: 11762551     EISSN: 11762551     Source Type: Journal    
DOI: 10.2165/00139709-200625020-00002     Document Type: Review

References (60)

1. Darke S, Zador D. Fatal heroin 'overdose': a review. Addiction 1996; 91: 1765-72
2. Warner-Smith M, Darke S, Lynskey M, et al. Heroin overdose: causes and consequences. Addiction 2001; 96: 1113-25
3. Sporer KA. Buprenorphine: a primer for emergency physicians. Ann Emerg Med 2004; 43: 580-4
4. Auriacombe M, Fatseas M, Dubernet J, et al. French field experience with buprenorphine. Am J Addict 2004; 13 Suppl. 1: S17-28
5. Feroni I, Aubisson S, Bouhnik AD, et al. Collaboration between general practitioners and pharmacists in the management of patients on high-dosage buprenorphine treatment: prescribers' practices [in French]. Presse Med 2005; 34: 1213-9
6. Gueye PN, Mégarbane B, Borron SW, et al. Trends in opiate and opioid poisonings in addicts in north-east Paris and suburbs, 1995-99. Addiction 2000; 97: 1295-304
7. Emmanuelli J, Desenclos JC. Harm reduction interventions, behaviors and associated health outcomes in France, 1996-2003. Addiction 2005; 100: 1690-700
8. Reisine T, Pasternak G. Opioid analgesics and antagonists. In: Hardman J, Limbird L, Molinoff P, et al., editors. Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 521-55
9. Huang P, Kehner GB, Cowan A, et al. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001; 297: 688-95
10. Boas RA, Villiger JW. Clinical actions of fentanyl and buprenorphine: the significance of receptor binding. Br J Anaesth 1985; 57: 192-6
11. Boysen K, Hertel S, Chraemmer-Jorgensen B, et al. Buprenorphine antagonism of ventilatory depression following fentanyl anaesthesia. Acta Anaesthesiol Scand 1988; 32: 490-2
12. Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 2005; 44: 661-80
13. Chang Y, Moody DE, McCance-Katz EF. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab Dispos 2006; 34: 440-8
14. Obadia Y, Perrin V, Feroni I, et al. Injecting misuse of buprenorphine among french drug users. Addiction 2001; 96: 267-72
15. Comer SD, Collins ED, Fischman MW. Intravenous buprenorphine self-administration by detoxified heroin abusers. J Pharmacol Exp Ther 2001; 301: 266-76
16. Jenkinson RA, Clark NC, Fry CL, et al. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 2005; 100: 197-205
17. Robinson GM, Dukes PD, Robinson BJ, et al. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug Alcohol Depend 1993; 33: 81-6
18. Reynaud M, Tracqui A, Petit G, et al. Six deaths linked to misuse of buprenorphine-benzodiazepine combinations. Am J Psychiatry 1998; 155: 448-9
19. Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol 1998; 22: 430-4
20. Gaulier JM, Marquet P, Lacassie E, et al. Fatal intoxication following self-administration of a massive dose of buprenorphine. J Forensic Sci 2000; 45: 226-8
21. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int 2001; 121: 65-9
22. Kintz P. A new series of 13 buprenorphine-related deaths. Clin Biochem 2002; 35: 513-6
23. Pirnay S, Borron SW, Giudicelli CP, et al. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 2004; 99: 978-88
24. Steentoft A, Teige B, Holmgren P, et al. Fatal poisoning in Nordic drug addicts in 2002. Forensic Sci Int 2006; 160 (2-3): 148-56
25. Schifano F, Corkery J, Gilvarry E, et al. Buprenorphine mortality, seizures and prescription data in the UK, 1980-2002. Hum Psychopharmacol 2005; 20: 343-8
26. Serfaty M, Masterton G. Fatal poisonings attributed to benzodiazepines in Britain during the 1980s. Br J Psychiatry 1993; 163: 386-93
27. Cowan A, Doxey J, Harry E. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol 1977; 60: 547-54
28. Verborgh C, De Coster R, D'Haese J, et al. Effects of chlordiazepoxide on opioid-induced antinociception and respiratory depression in restrained rats. Pharmacol Biochem Behav 1998; 59: 663-70
29. McCormick GY, White WJ, Zagon IS, et al. Effects of diazepam on arterial blood gas concentrations and pH of adult rats acutely and chronically exposed to methadone. J Pharmacol Exp Ther 1984; 230: 353-9
30. Ohtani M, Kotaki H, Nishitateno K, et al. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 1997; 281: 428-33
31. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55: 569-80
32. Nielsen S, Taylor DA. The effect of buprenorphine and benzodiazepines on respiration in the rat. Drug Alcohol Depend 2005; 79: 95-101
33. Gueye PN, Borron SW, Ris̀ede P, et al. Lack of effect of single high doses of buprenorphine on arterial blood gases in the rat. Toxicol Sci 2001; 62: 148-54
34. Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006; 96: 627-32
35. Dahan A, Yassen A, Bijl H, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 2005; 94: 825-34
36. Molke Jensen F, Jensen NH, Holk IK, et al. Prolonged and biphasic respiratory depression following epidural buprenorphine. Anaesthesia 1987; 42: 470-5
37. Cicero TJ, Inciardi JA. Potential for abuse of buprenorphine in office-based treatment of opioid dependence. N Engl J Med 2005; 353: 1863-4
38. Rainey HB. Abuse of buprenorphine. N Z Med J 1986; 99: 72
39. Boyd J, Randell T, Luurila H, et al. Serious overdoses involving buprenorphine in Helsinki. Acta Anaesthesiol Scand 2003; 47: 1031-3
40. Gal TJ. Naloxone reversal of buprenorphine-induced respiratory depression. Clin Pharmacol Ther 1989; 45: 66-71
41. Ohtani M, Kotaki H, Uchino K, et al. Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats. Drug Metab Dispos 1994; 22: 2-7
42. Ohtani M, Kotaki H, Sawada Y, et al. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1995; 272: 505-10
43. Mégarbane B, Marie N, Pirnay S, et al. Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol Appl Pharmacol 2006; 212: 256-67
44. Gopal S, Tzeng TB, Cowan A. Characterization of the pharmacokinetics of buprenorphine and norbuprenorphine in rats after intravenous bolus administration of buprenorphine. Eur J Pharm Sci 2002; 15: 287-9
45. Debruyne D, Quentin T, Poisnel G, et al. Acute and chronic administration of clorazepate modifies the cell surface regulation of mu opioid receptors induced by buprenorphine in specific regions of the rat brain. Brain Res 2005; 1052: 222-31
46. Quentin T, Debruyne D, Lelong-Boulouard V, et al. Clorazepate affects cell surface regulation of delta and kappa opioid receptors, thereby altering buprenorphine-induced adaptation in the rat brain. Brain Res 2005; 1063: 84-95
47. Borron SW, Monier C, Risède P, et al. Flunitrazepam variably alters morphine, buprenorphine, and methadone lethality in the rat. Hum Exp Toxicol 2002; 21: 599-605
48. Gueye PN, Borron SW, Risède P, et al. Buprenorphine and midazolam act in combination to depress respiration in rats. Toxicol Sci 2002; 65: 107-14
49. Shah N, Patel V, Donald A. Effect of diazepam, desmethylimipramine, and SKF 525-A on the disposition of levo-methadone in mice after single or double injection. Drug Metab Dispos 1979; 7: 241-2
50. Pond SM, Tong TG, Benovitz NL, et al. Lack of effect of diazepam on methadone metabolism in methadone-maintained addicts. Clin Pharmacol Ther 1982; 31: 139-43
51. Ibrahim RB, Wilson JG, Thorsby ME, et al. Effect of buprenorphine on CYP3A activity in rat and human liver microsomes. Life Sci 2000; 66: 1293-8
52. Kilicarslan T, Sellers EM. Lack of interaction of buprenorphine with flunitrazepam metabolism. Am J Psychiatry 2000; 157: 1164-6
53. Mégarbane B, Pirnay S, Borron SW, et al. Flunitrazepam does not alter cerebral distribution of buprenorphine in the rat. Toxicol Lett 2005; 157: 211-9
54. Kalyuzhny AE, Dooyema J, Wessendorf MW. Opioid- and GABA(A)-receptors are co-expressed by neurons in rat brain. Neuroreport 2000; 11: 2625-8
55. Yamada KA, Norman WP, Hamosh P, et al. Medullary ventral surface GABA receptors affect respiratory and cardiovascular function. Brain Res 1982; 248: 71-8
56. Dan'ura T, Kurokawa T, Yamashita A, et al. Inhibition of rat brain adenylate cyclase activity by benzodiazepine through the effects on Gi and catalytic proteins. Life Sci 1988; 42: 469-75
57. Yanez A, Sabbe MB, Stevens CW, et al. Interaction of midazolam and morphine in the spinal cord of the rat. Neuropharmacology 1990; 29: 359-64
58. Cox RF, Collins MA. The effects of benzodiazepines on human opioid receptor binding and function. Anesth Analg 2001; 93: 354-8
59. Gueye PN, Lofaso F, Borron SW, et al. Mechanism of respiratory insufficiency in pure or mixed drug-induced coma involving benzodiazepines. J Toxicol Clin Toxicol 2002; 40: 35-47
60. Catley DM, Thornton C, Jordan C, et al. Pronounced, episodic oxygen desaturation in the postoperative period: its association with ventilatory pattern and analgesic regimen. Anesthesiology 1985; 63: 20-8